Clinical Trial Update: A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients [Phase 3]

View source ↗

Summary

Durvalumab was studied as consolidation therapy in non-small cell lung cancer in a Phase 3 trial, with results posted in 2025. The results were posted on 2025-0…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-12